Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Approves Addyi, Rejects Gender Discrimination Claims

This article was originally published in RPM Report

Executive Summary

FDA knew its decision on whether to approve the first treatment for female sexual dysfunction would be controversial. The Division Director's memo explaining the decision and acknowledging the controversy makes for interesting reading.


Related Content

Sprout's Flibanserin Gets Reluctant Nod From FDA Panel, But REMS Needed
A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors


Related Companies